[{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"0c9c74d6-485b-4485-94f9-eb7a56d84916","acronym":"","url":"https://clinicaltrials.gov/study/NCT06549634","created_at":"2025-02-25T16:48:12.139Z","updated_at":"2025-02-25T16:48:12.139Z","phase":"","brief_title":"Biomarkers of AKI in Patients Receiving Daratumumab","source_id_and_acronym":"NCT06549634","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" DKK3","pipe":"","alterations":" ","tags":["DKK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-05"},{"id":"3339f750-4360-456a-b1ee-c276f0735a58","acronym":"","url":"https://clinicaltrials.gov/study/NCT03473730","created_at":"2021-01-18T17:07:06.521Z","updated_at":"2025-02-25T17:29:38.839Z","phase":"Phase 1","brief_title":"Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03473730","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/29/2018","start_date":" 05/29/2018","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-01-30"},{"id":"b2fc6887-a084-4aa0-93a1-942ca0ac28d0","acronym":"MUKnineb","url":"https://clinicaltrials.gov/study/NCT03188172","created_at":"2021-01-18T15:43:10.893Z","updated_at":"2025-02-25T14:26:26.313Z","phase":"Phase 2","brief_title":"MUK Nine b: OPTIMUM Treatment Protocol","source_id_and_acronym":"NCT03188172 - MUKnineb","lead_sponsor":"University of Leeds","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • melphalan • Neupogen (filgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-05-14"},{"id":"d2b7a6bc-a50d-43d6-9188-90e486052fd6","acronym":"CheckMate142","url":"https://clinicaltrials.gov/study/NCT02060188","created_at":"2021-01-17T17:13:48.793Z","updated_at":"2024-07-02T16:35:04.397Z","phase":"Phase 2","brief_title":"A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread","source_id_and_acronym":"NCT02060188 - CheckMate142","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cotellic (cobimetinib) • Darzalex (daratumumab) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 385","initiation":"Initiation: 03/12/2014","start_date":" 03/12/2014","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-05-10"},{"id":"94c8991a-5401-4521-bceb-f4667098ab6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03035357","created_at":"2021-01-18T14:56:23.113Z","updated_at":"2024-07-02T16:35:06.269Z","phase":"Phase 2","brief_title":"Neoadjuvant Listeria or Daratumumab in Prostate Cancer","source_id_and_acronym":"NCT03035357","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD68","pipe":"","alterations":" ","tags":["CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2024-05-03"},{"id":"7a7e78ae-33bd-4583-a3bd-e69587f5d1ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556332","created_at":"2021-01-18T17:30:18.830Z","updated_at":"2024-07-02T16:35:14.241Z","phase":"Phase 2","brief_title":"A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT03556332","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-03-18"},{"id":"c19d8f37-59b1-415c-8978-46cc1e9175a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05308654","created_at":"2022-04-04T14:52:53.458Z","updated_at":"2024-07-02T16:35:22.296Z","phase":"Phase 1","brief_title":"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets","source_id_and_acronym":"NCT05308654","lead_sponsor":"AbbVie","biomarkers":" BCL2","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • surzetoclax (ABBV-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2024-01-25"},{"id":"67a15808-0681-4add-b990-145069d8cdb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714372","created_at":"2021-01-19T20:53:07.373Z","updated_at":"2024-07-02T16:35:23.907Z","phase":"Phase 1","brief_title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","source_id_and_acronym":"NCT04714372","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • IDH1 • IDH2 • CD38","pipe":" | ","alterations":" CD38 expression","tags":["FLT3 • IDH1 • IDH2 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 01/09/2024","primary_completion_date":" 01/09/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2024-01-10"},{"id":"fd9ebc09-6d35-46a3-abd9-f9c124160735","acronym":"EAE120","url":"https://clinicaltrials.gov/study/NCT05280275","created_at":"2022-03-15T18:52:55.764Z","updated_at":"2025-02-25T13:12:55.381Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible","source_id_and_acronym":"NCT05280275 - EAE120","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/13/2022","start_date":" 04/13/2022","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/15/2026","study_completion_date":" 03/15/2026","last_update_posted":"2023-12-01"},{"id":"6a45c024-4c0a-472b-844c-1cfb591a4381","acronym":"CheckMate 039","url":"https://clinicaltrials.gov/study/NCT01592370","created_at":"2022-02-17T15:52:52.744Z","updated_at":"2024-07-02T16:35:37.075Z","phase":"Phase 1/2","brief_title":"An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma","source_id_and_acronym":"NCT01592370 - CheckMate 039","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Darzalex (daratumumab) • dexamethasone • pomalidomide • lirilumab (BMS-986015)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 08/02/2012","start_date":" 08/02/2012","primary_txt":" Primary completion: 09/25/2020","primary_completion_date":" 09/25/2020","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2023-09-13"},{"id":"295b0561-593e-4af2-bcb7-0b0537450f29","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896737","created_at":"2021-01-18T19:11:30.460Z","updated_at":"2024-07-02T16:35:37.895Z","phase":"Phase 2","brief_title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","source_id_and_acronym":"NCT03896737","lead_sponsor":"European Myeloma Network","biomarkers":" IGH","pipe":" | ","alterations":" IGH translocation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 401","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-09-07"},{"id":"9553b380-cc34-4290-aa5f-0fb22fe4ee0f","acronym":"AMC-105","url":"https://clinicaltrials.gov/study/NCT04139304","created_at":"2021-01-29T07:19:53.416Z","updated_at":"2024-07-02T16:35:38.442Z","phase":"Phase 1","brief_title":"A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma","source_id_and_acronym":"NCT04139304 - AMC-105","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Darzalex (daratumumab) • vincristine • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2023-08-31"},{"id":"0304f43d-f70b-4b56-adac-e447768adbc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03346135","created_at":"2021-01-18T16:31:26.509Z","updated_at":"2024-07-02T16:35:39.907Z","phase":"Phase 2","brief_title":"Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma","source_id_and_acronym":"NCT03346135","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab) • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/17/2019","start_date":" 07/17/2019","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2025","study_completion_date":" 07/17/2025","last_update_posted":"2023-08-16"},{"id":"cbd8126f-1de2-4e9d-af74-9742ded7b1d0","acronym":"DETER-SMM","url":"https://clinicaltrials.gov/study/NCT03937635","created_at":"2021-01-18T19:23:30.202Z","updated_at":"2024-07-02T16:35:44.833Z","phase":"Phase 3","brief_title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","source_id_and_acronym":"NCT03937635 - DETER-SMM","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(4;14)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 09/16/2019","start_date":" 09/16/2019","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2023-06-23"},{"id":"1a20e268-2930-4294-b911-885f239ea93c","acronym":"DILEMMA","url":"https://clinicaltrials.gov/study/NCT05835726","created_at":"2023-04-28T15:04:55.549Z","updated_at":"2024-07-02T16:35:49.208Z","phase":"","brief_title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","source_id_and_acronym":"NCT05835726 - DILEMMA","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CD38 • CD34","pipe":" | ","alterations":" CD38 expression","tags":["CD38 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Darzalex (daratumumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-05-01"},{"id":"e0e4de6a-7e41-45c6-ab5e-ea8bda97f3ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT03187262","created_at":"2021-01-18T15:42:57.402Z","updated_at":"2024-07-02T16:35:59.988Z","phase":"Phase 2","brief_title":"A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia","source_id_and_acronym":"NCT03187262","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-11-23"},{"id":"af618ed1-f3a8-4f1c-b68f-d34b62bb09f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05581875","created_at":"2022-10-17T14:56:46.978Z","updated_at":"2025-02-25T13:13:10.924Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory","source_id_and_acronym":"NCT05581875","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/20/2022","start_date":" 10/20/2022","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2022-10-17"},{"id":"b1d5a974-0b04-421b-8acb-a796d504456e","acronym":"IDA53","url":"https://clinicaltrials.gov/study/NCT03734198","created_at":"2021-01-18T18:17:21.383Z","updated_at":"2024-07-02T16:36:08.182Z","phase":"Phase 2","brief_title":"Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction","source_id_and_acronym":"NCT03734198 - IDA53","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" TP53 • CD38","pipe":" | ","alterations":" TP53 mutation • CD38 expression","tags":["TP53 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Darzalex (daratumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-06-28"},{"id":"efbfe9eb-4524-40e9-a261-a132cfb2739a","acronym":"DARZALEX","url":"https://clinicaltrials.gov/study/NCT03023423","created_at":"2021-01-18T14:52:40.522Z","updated_at":"2024-07-02T16:36:53.389Z","phase":"Phase 1b/2","brief_title":"A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03023423 - DARZALEX","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Darzalex (daratumumab)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/23/2016","start_date":" 12/23/2016","primary_txt":" Primary completion: 05/17/2018","primary_completion_date":" 05/17/2018","study_txt":" Completion: 09/26/2019","study_completion_date":" 09/26/2019","last_update_posted":"2019-11-20"},{"id":"549a1ef6-eba8-48b1-bfb4-4b61cafd2aa1","acronym":"REBUILD","url":"https://clinicaltrials.gov/study/NCT03475628","created_at":"2021-01-18T17:07:31.443Z","updated_at":"2024-07-02T16:37:12.839Z","phase":"Phase 2","brief_title":"Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03475628 - REBUILD","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" DKK1 • CCL3","pipe":"","alterations":" ","tags":["DKK1 • CCL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 57","initiation":"Initiation: 02/21/2018","start_date":" 02/21/2018","primary_txt":" Primary completion: 06/20/2019","primary_completion_date":" 06/20/2019","study_txt":" Completion: 02/20/2020","study_completion_date":" 02/20/2020","last_update_posted":"2018-03-23"}]